"Chymases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of neutral serine proteases with CHYMOTRYPSIN-like activity. Chymases are primarily found in the SECRETORY GRANULES of MAST CELLS and are released during mast cell degranulation.
| Descriptor ID |
D053818
|
| MeSH Number(s) |
D08.811.277.656.300.760.103 D08.811.277.656.959.350.103
|
| Concept/Terms |
Chymases- Chymases
- Chymase
- Chymotrypsin-Like Proteases
- Chymotrypsin Like Proteases
- Chymotrypsin-Like Protease
- Chymotrypsin Like Protease
- Chymase-1
- Chymase 1
|
Below are MeSH descriptors whose meaning is more general than "Chymases".
Below are MeSH descriptors whose meaning is more specific than "Chymases".
This graph shows the total number of publications written about "Chymases" by people in this website by year, and whether "Chymases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 0 | 1 | 1 |
| 2021 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Chymases" by people in Profiles.
-
Structure-based virtual screening suggests inhibitors of 3-Chymotrypsin-Like Protease of SARS-CoV-2 from Vernonia amygdalina and Occinum gratissimum. Comput Biol Med. 2021 09; 136:104671.
-
Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021 11; 9(11):1299-1312.
-
Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir. J Gen Virol. 2021 07; 102(7).
-
Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients. Future Microbiol. 2020 12; 15:1747-1758.
-
Kinins and chymase: the forgotten components of the renin-angiotensin system and their implications in COVID-19 disease. Am J Physiol Lung Cell Mol Physiol. 2021 03 01; 320(3):L422-L429.
-
Biochemical and biophysical characterization of the main protease, 3-chymotrypsin-like protease (3CLpro) from the novel coronavirus SARS-CoV 2. Sci Rep. 2020 12 17; 10(1):22200.
-
Phytochemicals against SARS-CoV as potential drug leads. Biomed J. 2021 03; 44(1):74-85.
-
Caffeine and caffeine-containing pharmaceuticals as promising inhibitors for 3-chymotrypsin-like protease of SARS-CoV-2. J Biomol Struct Dyn. 2022 Mar; 40(5):2113-2120.
-
Polyphenols vs. Coronaviruses: How Far Has Research Moved Forward? Molecules. 2020 Sep 08; 25(18).
-
Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease. FEBS Open Bio. 2020 06; 10(6):995-1004.